Preview

Cancer Urology

Advanced search

SEQUENTIAL USE OF TARGET AGENTS AND THEIR COMBINATION IN THE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA

https://doi.org/10.17650/1726-9776-2010-6-4-16-22

Abstract

The development of molecular biology led to the discovery of major pathogenetic pathways in the development of renal cell carcinoma (RCC), contributing to the designing of novel drugs to treat metastatic RCC, which belong to a group of target agents or tyrosine kinase inhibitors. Phases II and III clinical trials have proven the efficacy and controlled safety profile of a broad range of drugs for the treatment of metastatic RCC. The developing resistance to drugs and their intolerance determine the need to conduct new clinical studies and to search for novel agents and treatment regimens to improve survival and quality of life in patients. The performed studies of the efficiency and safety of sequential use of antiangiogenic drugs and their combination have supported that it is expedient to apply these treatment policies to patients with metastatic RCC. The expected results from the ongoing large Phase III clinical trials will let one find out how to optimally use target agents, in what combination or in what sequence.

About the Authors

B. Ya. Alekseyev
P.A. Herzen Moscow Research Oncological Institute, Russian Agency for Medical Technologies
Russian Federation


A. S. Kalpinsky
P.A. Herzen Moscow Research Oncological Institute, Russian Agency for Medical Technologies
Russian Federation


References

1. Cohen H., McGovern F. Renal Cell carcinoma. N Engl J Med 2005;353:3477–90.

2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году. М., 2010.

3. Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82–7.

4. Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell arcinoma. Eur Urol 2008;54, issue 2:315–25.

5. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45.

6. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109–14.

7. Ljungberg B., Cowan N., Hanbury D.C. et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org Доступно в сети Интернет с апреля 2010 г.

8. NCCN clinical practice guidelines in oncology: kidney cancer (V.2.2010). National Comprehensive Cancer Network Web site. http://www.nccn.org. Доступно в сети Интернет.

9. Bracarda S., De Simone V. Sequential therapies in metastatic renal cell carcinoma:option or strategy? Eur Urol 2008; 54:1219–22.

10. Bellmunt J. Future developments in renal cell carcinoma. Ann Onc 2009;20:i13–17.

11. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.

12. Tamaskar I., Garcia J.A., Elson P. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81–6.

13. Shepard D.R., Rini B.I., Garcia J.A. et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26 (20 suppl);abstr 5123.

14. Rini B.I., Michaelson M.D.,Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.

15. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.

16. Escudier B., Ravaud A., Oudard S. et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 720]. Ann Oncol 2008;19:viii45.

17. Motzer R., Kay A., Figlin R. et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [abstract 278]. American Society of Clinical Oncology Web site. http://www.asco.org. Доступно в сети

18. Интернет с июня 2009 г.

19. Dutcher J.P., Wild D., Hudes G.R. et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 2008;26(20 Suppl);abstr 5127.

20. Rini B.I., Wilding G., Hudes G. et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462–8.

21. Sablin M., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007 (20 Suppl);abstr 5038.

22. Escudier B., Goupil M.G., Massard C. et al. Sequential therapy in renal cell carcinoma. Cancer 2009; 115(10 suppl):2321–6. 22. www.clinicaltrials.gov. Доступно в сети Интернет.

23. Sosman J., Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009;115(10 Suppl):2368–75.

24. Sternberg C.N., Bellmunt J., Grunwald V. et al. Advances in the management of metastatic renal cell cancer. Eur Urol Suppl 2009;8:758–61.

25. Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889–96.

26. Hainsworth J.D., Spigel D.R., Sosman J.A. et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007;5:427–32.

27. Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536–41.

28. Sosman J.A., Flaherty K.T., Atkins M.B et al. Updated results of phase I trial of sorafenib (S) and evacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 5011.

29. Whorf R.C., Hainsworth J.D., Spigel D.R. et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 5010.

30. Merchan J.R., Liu G., Fitch T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract]. J Clin Oncol 2007;25(18S); abstr 5034.

31. Feldman D.R., Ginsberg M.S., Baum M. et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2008;26(20 suppl);abstr 5100.

32. Cooney M.M., Garcia J.A., Elson P. et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 3530.

33. Feldman D.R., Baum Michael S., Ginsberg Michelle S. et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432–9.

34. Fischer P., Patel P., Carducci M.A. et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma [abstr.]. J Clin Oncol 2008;26(20 suppl);abstr 16020.

35. Hainsworth J.D., Spigel D.R., Burris H.A. et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28(13):2131–6.

36. Escudier B.J., Negrier S., Gravis G. et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010;28(15 Suppl):4516.


Review

For citations:


Alekseyev B.Ya., Kalpinsky A.S. SEQUENTIAL USE OF TARGET AGENTS AND THEIR COMBINATION IN THE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA. Cancer Urology. 2010;6(4):16-22. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-4-16-22

Views: 867


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X